The Sunday Brief · Issue №32 · August 9, 2026
Semaglutide's kidney signal gets its strongest pooled evidence yet — and a rat study gets ahead of itself
5 min read · Week of August 3–9, 2026
The week's most consequential readout is a prespecified pooled analysis of individual patient data from SELECT, FLOW, and SOUL — nearly 31,000 people — in which semaglutide was associated with a 16% lower likelihood of a serious kidney endpoint over roughly three to four years. That matters because kidney protection has largely been inferred from single trials in narrower populations; pooling three placebo-controlled trials at the patient level moves it from suggestive to substantial, across both injectable and oral dosing.
Research Spotlight
This week's human evidence is unusually strong and unusually concentrated: four of the five leading entries are randomised-trial or pooled-trial data, and nearly all of it sits in the GLP-1 metabolic space. The kisspeptin trial is the outlier worth noting — a small, mechanistically careful human study in an entirely different axis. The one preclinical entry drawing attention is a rat model, and the gap between its detail and its applicability is this week's calibration exercise.
Pooled patient data from SELECT, FLOW, and SOUL: 16% lower risk of a serious kidney endpoint
Researchers combined individual patient data from three large placebo-controlled semaglutide trials covering nearly 31,000 people with heart, kidney, or metabolic disease. Over roughly three to four years, participants on semaglutide were 16% less likely to reach a serious kidney endpoint — a major decline in kidney function, kidney failure, or kidney- or cardiovascular-related death — than those on placebo. Side effects were similar to those reported in earlier GLP-1 trials, and the association held whether the drug was injected or taken orally.
Pooling 24 phase 3 trials of a year or longer, this network meta-analysis ranked tirzepatide 15 mg highest for weight and waist-circumference reduction, with the newer 7.2 mg semaglutide dose edging out 2.4 mg by a modest two to three percentage points. Serious adverse events did not differ meaningfully between the compounds. Network meta-analyses compare drugs that were rarely tested head to head, so the ranking is an indirect one — informative for magnitude, weaker for fine distinctions between adjacent doses.
Kisspeptin-10 sustained gonadotropin release for 12 days — but only with intermittent dosing
In a randomised, single-blinded, placebo-controlled study, 15 healthy men received three subcutaneous kisspeptin-10 regimens against 12 controls, with luteinising hormone, follicle stimulating hormone, and testosterone measured throughout. Acute eight-hour infusions raised all three dose-dependently. Continuous infusion over five days kept testosterone elevated but let gonadotropins fall back to placebo levels, while eight-hours-on, sixteen-hours-off dosing sustained the gonadotropin rise across twelve days. A closing bolus still produced a response, indicating the receptor stayed responsive.
This systematic review and meta-analysis pooled 388 patients across 19 studies, most of them receiving dialysis, with semaglutide the most represented agent. Weight fell about 3.1 kg at three months, 3.7 kg at six months, and 7.0 kg at twelve months, and HbA1c was down 0.75 points at a year. Adverse events were reported in 44% of semaglutide patients, predominantly gastrointestinal, and 9% discontinued because of them. The pooled sample is small and largely observational in composition, so the estimates are early rather than settled.
Signal vs noise: SS-31 restored memory in aged rats — that is an animal model, not a human finding
The week's most-discussed item is also its weakest evidence: an animal study in aged rats undergoing surgery with perioperative morphine. Researchers observed loss of stable dendritic spine subtypes, impaired long-term potentiation, and hippocampal mitochondria with impaired oxidative phosphorylation. The mitochondria-targeted peptide SS-31, given four weeks after surgery, restored hippocampal-dependent memory and normalised mitochondrial respiration, though DNA oxidation stayed elevated. Preclinical rodent work of this kind establishes mechanism, not human applicability.
Community Watch
Community attention this week was dominated by retatrutide, and the shape of that attention is worth noting: most of the volume is a single educational post recirculating across regional biohacking and weight-loss subreddits rather than independent reports of use. The genuinely original threads are questions, not findings — administration routes and plateau troubleshooting. These are community discussions and self-reports, not evidence of any outcome.
Users ask whether retatrutide can be delivered by atomizer instead of injection
A thread in r/Biohacking asks whether anyone has experience using retatrutide via an atomizer rather than injection, probing the community on the viability of an alternative administration route. No outcome data or bioavailability evidence is presented — the thread is a question. Route-of-administration substitution for an investigational compound sits well outside anything studied in the published literature.
One retatrutide primer, crossposted across four regional communities
The same educational series entry on retatrutide appeared across r/BiohackPhilippines, r/TirzepatidePH, and r/WeightLossPhilippines, framing the investigational triple-agonist as an advanced tier in a progression of metabolic compounds. The apparent surge in retatrutide discussion is largely one post's reach rather than a broadening base of user reports — a distinction worth holding when volume is mistaken for consensus.
A plateau thread: last five pounds holding despite a GLP-1 compound, training, and diet
A 33-year-old woman in r/BodyHackGuide reports a stubborn plateau on the final five pounds despite a GLP-1 compound, unspecified additional peptides, structured training, and diet. The specific compounds are not named. Threads like this are the most common pattern in community forums and the least interpretable: without named compounds, doses, or duration, there is nothing to compare against the trial data above.
One thing to think about
The split this week is stark. The strongest human evidence is almost entirely GLP-1 and semaglutide-adjacent, while community attention concentrated on retatrutide — a compound with no human trial data in this week's candidate set at all. Attention and evidence are moving in different directions, and the gap is where unfounded expectations tend to form.
Get the next issue
Subscribe to The Sunday Brief
Every Sunday: what the studies say, what the community is finding, and which vendors are credible — straight to your inbox.
Free. Unsubscribe anytime. No affiliate links. No spam.